According to the research report titled ‘Haematococcus Pluvialis Market by Product (Astaxanthin Ingredients {Oleoresin, Beadlets}), Astaxanthin Bulk Finished Products {Capsules, Tablets}); Application (Nutraceuticals, Aquaculture, Cosmetics, Food), and Geography - Global Forecast to 2030,’ in terms of value, the haematococcus pluvialis market is projected to reach $189.8 million by 2030, at a CAGR of 13.3% from 2023 to 2030, while in terms of volume, this market is projected to reach 1,369.9 tons by 2030, at a CAGR of 14.8% from 2023 to 2030. The report provides an in-depth analysis of the haematococcus pluvialis market across five major geographies, current market trends, recent developments, and the market size & forecast till 2030.
Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.
The growth of this market is driven by increasing demand for natural astaxanthin for nutraceuticals, growing natural food colorant’s demand, and increasing awareness for clean-label products. However, the high production cost is expected to restrain the growth of this market. The growing demand for natural astaxanthin and its use in poultry and aquaculture is expected to create market growth opportunities. However, the complex production process for haematococcus pluvialis is a major challenge for the players operating in this market.
Based on product, the haematococcus pluvialis market is mainly segmented into astaxanthin ingredients and astaxanthin bulk finished products. In 2023, the astaxanthin ingredients segment is expected to account for the largest share of the global haematococcus pluvialis market. The large market share of this segment is mainly attributed to the growing end-use applications of astaxanthin ingredients, rising awareness about preventive healthcare & nutraceuticals, rising demand for natural antioxidants, growing cosmetic & personal care markets, and government initiatives to support the aquaculture industry.
Based on application, the haematococcus pluvialis market is segmented into nutraceuticals, aquaculture and animal feed, cosmetics, food and beverages, and pharmaceuticals. In 2023, the nutraceuticals segment is expected to account for the largest share of the global haematococcus pluvialis market. The large market share of this segment is mainly attributed to the growth of this segment are the growing end-use applications of astaxanthin ingredients, rising awareness about preventive healthcare & nutraceuticals, rising demand for natural antioxidants, growing cosmetic & personal care markets, and government initiatives to support the aquaculture industry.
An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. Asia-Pacific is expected to witness significant growth during the forecast period, mainly due to increasing health consciousness, growing nutraceutical and F&B industries, increasing demand for personal care products, and high investments for algae production offer significant opportunities for various stakeholders in the Asia-Pacific region. Also, the growing adoption of haematococcus pluvialis-derived products is fueling the growth of the nutraceutical industry.
The key players operating in the haematococcus pluvialis market are E.I.D. - Parry (India) Limited (A Subsidiary of M/S. Ambadi Investments Limited) (India), Cyanotech Corporation (U.S.), YUNNAN GREEN A BIOLOGICAL PROJECT CO., LTD. (Yunnan Spirin Biotechnology Co. Ltd) (China), Sun Chlorella Corporation (Japan), Roquette Klötze GmbH & Co. KG (Germany), Tianjin Norland Biotech Co., Ltd (China), Aliga Microalgae (Denmark), DAESANG Corporation (Korea), Plankton Australia Pty Limited (Australia), Shaanxi Rebecca Bio-Tech Co., Ltd (China), BlueBioTech Group (Germany), Algatechnologies Ltd. (A Part of Solabia Group) (Israel), AstaReal Group (Japan), Yunnan Alphy Biotech Co.,Ltd (China), Beijing Gingko Group (BGG) (U.S.), FENCHEM (China), PIVEG, Inc. (U.S.), Algamo s.r.o. (Czech Republic), Algalíf Iceland ehf. (Part of Sana Pharma Industries) (Iceland), Atacama Bio Natural Products S.A. (Chile), BDI BioLife Science GmbH (Austria), AstaMAZ NZ LTD (New Zealand), FjordAlg AS (Norway), Sea & Sun Organic GmbH (Subsidiary of Sea & Sun Technology GmbH) (Germany), MC Biotech Sdn. Bhd. (Brunei Darussalam), Pond Technologies Inc. (Canada), Algicel, Biotecnologia e Investigação, Lda (Portugal), Algae to Omega, LLC (U.S.), Shaivaa Algaetech LLP (India), and Astaxa GmbH (Germany).
Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.
The growth of this market is driven by increasing demand for natural astaxanthin for nutraceuticals, growing natural food colorant’s demand, and increasing awareness for clean-label products. However, the high production cost is expected to restrain the growth of this market. The growing demand for natural astaxanthin and its use in poultry and aquaculture is expected to create market growth opportunities. However, the complex production process for haematococcus pluvialis is a major challenge for the players operating in this market.
Based on product, the haematococcus pluvialis market is mainly segmented into astaxanthin ingredients and astaxanthin bulk finished products. In 2023, the astaxanthin ingredients segment is expected to account for the largest share of the global haematococcus pluvialis market. The large market share of this segment is mainly attributed to the growing end-use applications of astaxanthin ingredients, rising awareness about preventive healthcare & nutraceuticals, rising demand for natural antioxidants, growing cosmetic & personal care markets, and government initiatives to support the aquaculture industry.
Based on application, the haematococcus pluvialis market is segmented into nutraceuticals, aquaculture and animal feed, cosmetics, food and beverages, and pharmaceuticals. In 2023, the nutraceuticals segment is expected to account for the largest share of the global haematococcus pluvialis market. The large market share of this segment is mainly attributed to the growth of this segment are the growing end-use applications of astaxanthin ingredients, rising awareness about preventive healthcare & nutraceuticals, rising demand for natural antioxidants, growing cosmetic & personal care markets, and government initiatives to support the aquaculture industry.
An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. Asia-Pacific is expected to witness significant growth during the forecast period, mainly due to increasing health consciousness, growing nutraceutical and F&B industries, increasing demand for personal care products, and high investments for algae production offer significant opportunities for various stakeholders in the Asia-Pacific region. Also, the growing adoption of haematococcus pluvialis-derived products is fueling the growth of the nutraceutical industry.
The key players operating in the haematococcus pluvialis market are E.I.D. - Parry (India) Limited (A Subsidiary of M/S. Ambadi Investments Limited) (India), Cyanotech Corporation (U.S.), YUNNAN GREEN A BIOLOGICAL PROJECT CO., LTD. (Yunnan Spirin Biotechnology Co. Ltd) (China), Sun Chlorella Corporation (Japan), Roquette Klötze GmbH & Co. KG (Germany), Tianjin Norland Biotech Co., Ltd (China), Aliga Microalgae (Denmark), DAESANG Corporation (Korea), Plankton Australia Pty Limited (Australia), Shaanxi Rebecca Bio-Tech Co., Ltd (China), BlueBioTech Group (Germany), Algatechnologies Ltd. (A Part of Solabia Group) (Israel), AstaReal Group (Japan), Yunnan Alphy Biotech Co.,Ltd (China), Beijing Gingko Group (BGG) (U.S.), FENCHEM (China), PIVEG, Inc. (U.S.), Algamo s.r.o. (Czech Republic), Algalíf Iceland ehf. (Part of Sana Pharma Industries) (Iceland), Atacama Bio Natural Products S.A. (Chile), BDI BioLife Science GmbH (Austria), AstaMAZ NZ LTD (New Zealand), FjordAlg AS (Norway), Sea & Sun Organic GmbH (Subsidiary of Sea & Sun Technology GmbH) (Germany), MC Biotech Sdn. Bhd. (Brunei Darussalam), Pond Technologies Inc. (Canada), Algicel, Biotecnologia e Investigação, Lda (Portugal), Algae to Omega, LLC (U.S.), Shaivaa Algaetech LLP (India), and Astaxa GmbH (Germany).
Key Questions Answered in the Report:
- What is the value of revenue generated by the haematococcus pluvialis market?
- At what rate is the global demand for haematococcus pluvialis projected to grow for the next 5-7 years?
- What is the historical market size and growth rate for the haematococcus pluvialis market?
- What are the major factors impacting the growth of this market at global and regional levels?
- What are the major opportunities for existing players and new entrants in the market?
- What impact does the current COVID-19 pandemic have on the haematococcus pluvialis market?
- Which product and application segments create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the haematococcus pluvialis market?
- Who are the major players in the haematococcus pluvialis market? What are their specific product offerings in this market?
- What recent developments have taken place in the haematococcus pluvialis market? What impact have these strategic developments created on the market?
Scope of the Report:
Global Haematococcus Pluvialis Market, by Product
- Astaxanthin Ingredients
- Astaxanthin Oleoresin
- Beadlets
- Whole Biomass Powder
- Water Dispersible Powder
- Astaxanthin Bulk Finished Products
- Capsules/Softgels
- Tablets
Global Haematococcus Pluvialis Market, by Application
- Nutraceutical
- Aquaculture and Animal Feed
- Cosmetics
- Food & Beverages
- Pharmaceuticals
Global Haematococcus Pluvialis Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Italy
- France
- Sweden
- Spain
- Russia
- Netherlands
- Denmark
- Poland
- Rest of Europe (RoE)
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Vietnam
- Rest of Asia-Pacific (RoAPAC)
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America (RoLATAM)
- Middle East and Africa
- Israel
- Egypt
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Table of Contents
1. Market Definition & Scope
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Global Haematococcus Pluvialis Market Assessment - By Product
6. Global Haematococcus Pluvialis Market Assessment - By Application
7. Haematococcus Pluvialis Market Assessment - by Geography
8. Competition Analysis
9. Company Profiles
10. Appendix
List of Tables
List of Figures
Companies Mentioned
- E.I.D. - Parry (India) Limited (A Subsidiary of M/S. Ambadi Investments Limited) (India)
- Cyanotech Corporation (U.S.)
- YUNNAN GREEN A BIOLOGICAL PROJECT CO. Ltd. (Yunnan Spirin Biotechnology Co. Ltd) (China)
- Sun Chlorella Corporation (Japan)
- Roquette Klötze GmbH & Co. KG (Germany)
- Tianjin Norland Biotech Co. Ltd (China)
- Aliga Microalgae (Denmark)
- DAESANG Corporation (Korea)
- Plankton Australia Pty Limited (Australia)
- Shaanxi Rebecca Bio-Tech Co. Ltd (China)
- BlueBioTech Group (Germany)
- Algatechnologies Ltd. (A Part of Solabia Group) (Israel)
- AstaReal Group (Japan)
- Yunnan Alphy Biotech Co.,Ltd (China)
- Beijing Gingko Group (BGG) (U.S.)
- FENCHEM (China)
- PIVEG Inc. (U.S.)
- Algamo s.r.o. (Czech Republic)
- Algalíf Iceland ehf. (Part of Sana Pharma Industries) (Iceland)
- Atacama Bio Natural Products S.A. (Chile)
- BDI BioLife Science GmbH (Austria)
- AstaMAZ NZ LTD (New Zealand)
- FjordAlg AS (Norway)
- Sea & Sun Organic GmbH (Subsidiary of Sea & Sun Technology GmbH) (Germany)
- MC Biotech Sdn. Bhd. (Brunei Darussalam)
- Pond Technologies Inc. (Canada)
- Algicel Biotecnologia e Investigação Lda (Portugal)
- Algae to Omega LLC (U.S.)
- Shaivaa Algaetech LLP (India)
- Astaxa GmbH (Germany).